Bibliography

Found 23 results

Filters: Author is Clifford, David [Clear All Filters]

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

A

Sattler FR, He J, Letendre S, Wilson C, Sanders C, Heaton R, Ellis R, Franklin D, Aldrovandi G, Marra CM, et al. Abdominal obesity contributes to neurocognitive impairment in HIV-infected patients with increased inflammation and immune activation. J Acquir Immune Defic Syndr. 2015 ;68(3):281-8.

Clifford DB, Kauwe JSK, Teshome M, Shah A, Spinner M, Morris JC, Holtzman DM, Fagan A. Abnormal CSF Amyloid b42 Levels Link HIV-associated Cognitive Disease and Alzheimer's Disease. In: 15th Conference on Retroviruses and Opportunistic Infections. Abstract 396b. 15th Conference on Retroviruses and Opportunistic Infections. Boston, MA; 2008. p. 198.

Clifford DB, Vaida F, Kao Y-ting, Franklin D, Letendre S, Collier AC, Marra CM, Gelman B, McArthur JC, Morgello S, et al. Absence of neurocognitive effect of hepatitis C infection in HIV-coinfected people. Neurology. 2015 ;84(3):241-50.

Morgan EE, Woods SPaul, Letendre S, Franklin D, Bloss C, Goate A, Heaton RK, Collier AC, Marra CM, Gelman B, et al. Apolipoprotein E4 genotype does not increase risk of HIV-associated neurocognitive disorders. J Neurovirol. 2013 ;19(2):150-6.

Grant I, Franklin D, Deutsch R, Woods SPaul, Vaida F, Ellis RJ, Letendre S, Marcotte TD, Atkinson JH, Collier AC, et al. Asymptomatic HIV-associated neurocognitive impairment increases risk for symptomatic decline. Neurology. 2014 ;82(23):2055-62.

C

Ellis RJ, Badiee J, Vaida F, Letendre S, Heaton RK, Clifford D, Collier AC, Gelman B, McArthur J, Morgello S, et al. CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy. AIDS. 2011 ;25(14):1747-51.

Perez-Valero I, Ellis RJ, Heaton RK, Deutsch R, Franklin D, Clifford DB, Collier AC, Gelman B, Marra C, McCutchan JA, et al. Cerebrospinal fluid viral escape in aviremic HIV-infected patients receiving antiretroviral therapy: prevalence, risk factors and neurocognitive effects. AIDS. 2019 ;33(3):475-481.

Ellis RJ, Evans SR, Clifford DB, Moo LR, McArthur JC, Collier AC, Benson C, Bosch R, Simpson DM, Yiannoutsos CT, et al. Clinical validation of the NeuroScreen. Journal of Neurovirology [Internet]. 2005 ;11(6):503-11. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16338744

Bharti AR, Letendre SL, Wolfson T, Clifford D, Collier AC, Gelman B, McArthur J, Marra C, McCutchan A, Morgello S, et al. Clinical variables identify seronegative HCV co-infection in HIV-infected individuals. J Clin Virol. 2011 ;52(4):328-32.

Sakamoto M, Marcotte TD, Umlauf A, Franklin D, Heaton RK, Ellis RJ, Letendre S, Alexander T, McCutchan JA, Morgan EE, et al. Concurrent classification accuracy of the HIV dementia scale for HIV-associated neurocognitive disorders in the CHARTER Cohort. J Acquir Immune Defic Syndr. 2013 ;62(1):36-42.

Livelli A, Vaida F, Ellis RJ, Ma Q, Ferrara M, Clifford DB, Collier AC, Gelman B, Marra CM, McArthur JC, et al. Correlates of HIV RNA concentrations in cerebrospinal fluid during antiretroviral therapy: a longitudinal cohort study. Lancet HIV. 2019 ;6(7):e456-e462.

E

Lin K, Taylor MJ, Heaton R, Franklin D, Jernigan T, Fennema-Notestine C, McCutchan A, J Atkinson H, Ellis RJ, McArthur J, et al. Effects of traumatic brain injury on cognitive functioning and cerebral metabolites in HIV-infected individuals. J Clin Exp Neuropsychol. 2011 ;33(3):326-34.

Watson CWei-Ming, Kamalyan L, Hussain MA, Tang B, Collier AC, Clifford D, Gelman B, Sacktor NC, Morgello S, J McCutchan A, et al. Ethnic/racial differences in longitudinal neurocognitive change among people living with HIV. 2019 .

Nguyen A, Rossi S, Croteau D, Best BM, Clifford DB, Collier AC, Gelman B, Marra C, McArthur JC, McCutchan JA, et al. Etravirine in CSF is highly protein bound. J Antimicrob Chemother. 2013 ;68(5):1161-8.

Obermeit LC, Beltran J, Casaletto KB, Franklin DR, Letendre S, Ellis R, Fennema-Notestine C, Vaida F, Collier AC, Marra CM, et al. Evaluating the accuracy of self-report for the diagnosis of HIV-associated neurocognitive disorder (HAND): defining "symptomatic" versus "asymptomatic" HAND. J Neurovirol. 2017 ;23(1):67-78.

G

Joseph J, Achim C, Boivin MJ, Brew BJ, Clifford DB, Colosi DA, Ellis RJ, Heaton RK, Gallo-Diop A, Grant I, et al. Global NeuroAIDS roundtable. J Neurovirol. 2013 ;19(1):1-9.

I

Fennema-Notestine C, Ellis RJ, Archibald SL, Jernigan TL, Letendre S, Notestine RJ, Taylor MJ, Theilmann RJ, Julaton MD, Croteau D, et al. Increases in brain white matter abnormalities and subcortical gray matter are linked to CD4 recovery in HIV infection. J Neurovirol. 2013 ;19(4):393-401.

N

Marra CM, Deutsch R, Collier AC, Morgello S, Letendre S, Clifford DB, Gelman B, McArthur JC, McCutchan JA, Simpson DM, et al. Neurocognitive impairment in HIV-infected individuals with previous syphilis. Int J STD AIDS. 2013 ;24(5):351-5.

Saloner R, Campbell LM, Serrano V, Montoya JL, Pasipanodya E, Paolillo EW, Franklin D, Ellis RJ, Letendre S, Collier AC, et al. Neurocognitive SuperAging in Older Adults Living With HIV: Demographic, Neuromedical and Everyday Functioning Correlates. Journal of the International Neuropsychological Society [Internet]. 2019 . Available from: https://www.cambridge.org/core/terms. https://doi.org/10.1017/S1355617719000018

Cysique LA, Franklin D, Abramson I, Ellis RJ, Letendre S, Collier A, Clifford D, Gelman B, McArthur J, Morgello S, et al. Normative data and validation of a regression based summary score for assessing meaningful neuropsychological change. J Clin Exp Neuropsychol. 2011 ;33(5):505-22.

P

Joseph J, Clifford DB, Douglas SD, Fox HS, Gendelman HE, Gonzalez-Scarano F, Grant I, Major E, McArthur JC. Planning Future Strategies for Domestic and International NeuroAIDS Research, July 24-25, 2008. Journal of NeuroImmune Pharmacology [Internet]. 2009 ;4(3):283-297. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19455426

T

Croteau D, Letendre S, Best BM, Ellis RJ, Breidinger S, Clifford D, Collier A, Gelman B, Marra C, Mbeo G, et al. Total raltegravir concentrations in cerebrospinal fluid exceed the 50-percent inhibitory concentration for wild-type HIV-1. Antimicrob Agents Chemother. 2010 ;54(12):5156-60.

V

Letendre S, Marquie-Beck J, Capparelli E, Best B, Clifford D, Collier AC, Gelman BB, McArthur JC, J McCutchan A, Morgello S, et al. Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol. 2008 ;65(1):65-70.